The Role of p53 in Combination Radioimmunotherapy with ⁶⁴Cu-DOTA-Cetuximab and Cisplatin in a Mouse Model of Colorectal Cancer

Abstract

Together, these data suggest that (64)Cu specifically delivered to epidermal growth factor receptor-positive tumors by cetuximab can suppress tumor growth despite the KRAS status and present opportunities for personalized clinical treatment strategies in colorectal cancer.